K-K. Shiu

The genomic profile of <i>HER2</i>‐amplified breast cancers: the influence of ER status

Caterina Marchiò, Rachael Natrajan, K-K. Shiu et al. · The Journal of Pathology · 2008 · 75 citations

Medicine, Genetics, Oncology +16

VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

Sun Young Rha, L.S. Wyrwicz, P.E. Yanez Weber et al. · Annals of Oncology · 2023 · 66 citations · Full text

Medicine, Oncology, Pharmacology +13

Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers

Daniel Wetterskog, K-K. Shiu, Irene Chong et al. · Oncogene · 2013 · 52 citations · Full text

Medicine, Molecular Biology, Oncology +14

LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study

K-K. Shiu, Thierry André, Tae Won Kim et al. · Annals of Oncology · 2023 · 21 citations · Full text

Medicine, Oncology, Chemotherapy +13

LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)

Linda Mileshkin, Tilmann Bochtler, Chantal Pauli et al. · Annals of Oncology · 2023 · 20 citations · Full text

Medicine, Oncology, Pharmacology +17